A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer’s Disease
Abstract Advances in the understanding of Alzheimer’s disease (AD) suggest that pathogenesis is not directly related to plaque burden, but rather to soluble toxic amyloid-beta oligomers (AßO). Therapeutic antibodies targeting Aß monomers and/or plaque have shown limited efficacy and dose-limiting ad...
Guardado en:
Autores principales: | Ebrima Gibbs, Judith M. Silverman, Beibei Zhao, Xubiao Peng, Jing Wang, Cheryl L. Wellington, Ian R. Mackenzie, Steven S. Plotkin, Johanne M. Kaplan, Neil R. Cashman |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7e17d617f44d4cba8b63f9167f89ea62 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Role of Lipocalin-2 in Amyloid-Beta Oligomer-Induced Mouse Model of Alzheimer’s Disease
por: Heeyoung Kang, et al.
Publicado: (2021) -
A hydrogel biosensor for high selective and sensitive detection of amyloid-beta oligomers
por: Sun LP, et al.
Publicado: (2018) -
A Luminex assay detects amyloid β oligomers in Alzheimer's disease cerebrospinal fluid.
por: Adrianna Z Herskovits, et al.
Publicado: (2013) -
Multivariate analyses of amyloid-beta oligomer populations indicate a connection between pore formation and cytotoxicity.
por: Panchika Prangkio, et al.
Publicado: (2012) -
Oligodendrocytes damage in Alzheimer's disease: Beta amyloid toxicity and inflammation
por: ROTH,ALEJANDRO D, et al.
Publicado: (2005)